RGLS – regulus therapeutics inc. (US:NASDAQ)
Stock Stats
News
Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer
Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent Updates [Yahoo! Finance]
Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent Updates
Regulus Therapeutics Inc. (NASDAQ: RGLS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
Regulus Therapeutics Advances to Cohort 4 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Yahoo! Finance]
Form 4 Regulus Therapeutics For: May 16 Filed by: Collier Kathryn J
Form 4 Regulus Therapeutics For: May 16 Filed by: Nunn Jason Raleigh
Form 4 Regulus Therapeutics For: May 16 Filed by: Rosen Hugh
Form 4 Regulus Therapeutics For: May 16 Filed by: BALTIMORE DAVID
Form 4 Regulus Therapeutics For: May 16 Filed by: Witz Pascale
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.